Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.42 |
| ▸ | OXTR | P30559 | 6/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 3/20 | 0.37 |
| ▸ | KLRK1 | P26718 | 2/20 | 0.37 |
| ▸ | MICA | Q29983 | 2/20 | 0.37 |
| ▸ | RAET1L | Q5VY80 | 2/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8194590 | 0.93 | TACR1 (0.41) | TACR1OXTRSCN9ASLC6A9LIPE | |
| SCHEMBL1581627 | 0.92 | TACR1 (0.40) | TACR1OXTRLIPETRPM8NPC1 | |
| SCHEMBL8178945 | 0.90 | TACR1 (0.39) | TACR1OXTRLIPETRPM8NPC1 | |
| SCHEMBL264114 | 0.87 | TACR1 (0.39) | TACR1OXTRLIPETRPM8NPC1 | |
| SCHEMBL264116 | 0.87 | TACR1 (0.39) | TACR1OXTRLIPETRPM8NPC1 | |
| SCHEMBL264115 | 0.87 | TACR1 (0.39) | TACR1OXTRLIPETRPM8NPC1 | |
| SCHEMBL1581363 | 0.87 | TACR1 (0.51) | TACR1SLC6A9KLRK1MICARAET1L | |
| SCHEMBL1581562 | 0.84 | TACR1 (0.45) | TACR1SLC6A9KLRK1MICARAET1L | |
| SCHEMBL1581115 | 0.84 | TACR1 (0.45) | TACR1 | |
| SCHEMBL1581344 | 0.82 | TACR1 (0.44) | TACR1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121579-B1 | MALONAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-04-20 | — | — | EP | disclosed |
| US-7501541-B2 | Malonamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501541-B2 | Malonamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080249180-A1 | MALONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | US | disclosed |
| US-20080249180-A1 | MALONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249180-A1 | MALONAMIDES AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, MTNR1B | TACR1 57/4885OXTR 15/4885SCN9A 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.